Prenetics Execs Double Down with $1M Share Buy Amid Record Growth
Event summary
- Prenetics CEO Danny Yeung and CFO Brian Rosin purchased $1M of shares between August 20–25, 2026, following Q2 results.
- Cumulative leadership investment since November 2025 now totals $3.75M, with no shares sold during this period.
- Q2 2026 revenue hit $46.5M (up 288% YoY), with IM8 revenue at $45M (up 359% YoY).
- Company achieved first month of positive consolidated Adjusted Free Cash Flow in July 2026.
- Full-year 2026 revenue guidance raised to $220M–$230M, with 2027 guidance introduced at over $400M.
The big picture
Prenetics' leadership is doubling down on its stock amid record-breaking revenue growth and a strategic $1B investment from General Catalyst. The company's rapid scaling in the premium supplement sector—with IM8's annualized run-rate revenue nearing $251M—positions it as a disruptor in consumer health. The insider purchases underscore confidence in executing long-term growth plans, even as the market assesses the sustainability of such aggressive expansion.
What we're watching
- Leadership Alignment
- Whether continued insider buying signals confidence in sustaining current growth trajectory.
- Revenue Momentum
- The pace at which IM8 can maintain its rapid revenue expansion amid heightened competition.
- Capital Allocation
- How Prenetics deploys its $1B growth financing from General Catalyst to fuel further expansion.
Related topics